Nanoparticles: Characteristics, Mechanisms of Action, and Toxicity in Pulmonary Drug Delivery—A Review

Gill, Simardeep; Löbenberg, Raimar; Ku, Tabitha; Azarmi, Shirzad; Roa, Wilson; Prenner, Elmar J.

doi:10.1166/jbn.2007.015

Cited by 118Inhalation and Respiratory Drug DeliveryNanoparticle-Based Drug DeliveryAdvanced Drug Delivery Systems

Nanoparticles: Characteristics, Mechanisms of Action, and Toxicity in Pulmonary Drug Delivery—A Review

Gill, Simardeep, Löbenberg, Raimar, Ku, Tabitha, Azarmi, Shirzad, Roa, Wilson, Prenner, Elmar J.·2007·Journal of Biomedical Nanotechnology

DOI 10.1166/jbn.2007.015

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1166/jbn.2007.015

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The use of neutral nanoparticles as drug delivery vehicles is the most common approach in anti-TB therapy.
“The use of neutral NPs as drug delivery vehicles is the most common approach in anti-TB therapy.206”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [206]

Sorted by citations

Inhaled nanoparticles—A current review
Yang, W. P., Peters, J. I., & Williams, R. O. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.02.011 · Cited by 670 · see citing works
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645 · see citing works
“The use of neutral NPs as drug delivery vehicles is the most common approach in anti-TB therapy.(206) Ciprofloxacin encapsulated in liposomes has been employed in anti-TB therapy, offering pulmonary delivery through nebulization.”
Method
Targeted delivery of nanoparticles for the treatment of lung diseases
Azarmi, S., Roa, W. H., & Löbenberg, R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.006 · Cited by 440 · see citing works
Self-citation
Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates
Abdelaziz, H. M., Gaber, M. K., Elwakil, M. M. A., Mabrouk, M. T., Elgohary, M. M., Kamel, N. M., Kabary, D. M., Freag, M. S., Samaha, M. W., Mortada, S. M., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.036 · Cited by 409 · see citing works
Drug nanocrystals: in vivo performances.
Gao, L., Liu, G., Ma, J., Wang, X., Zhou, L., & Li, X. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.013 · Cited by 347 · see citing works
New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery
Sosnik, A., Carcaboso, A. M., Glisoni, R. J., Moretton, M. A., & Chiappetta, D. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.023 · Cited by 264 · see citing works
Formation, characterization, and fate of inhaled drug nanoparticles
Zhang, J., Wu, L., Chan, H., & Watanabe, W. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.11.002 · Cited by 210 · see citing works
Soybeans as a Phytochemical Reservoir for the Production and Stabilization of Biocompatible Gold Nanoparticles
Shukla, R., Nune, S. K., Chanda, N., et al. (2008) · Small · doi:10.1002/smll.200800525 · Cited by 201 · see citing works
Controlled pulmonary drug and gene delivery using polymeric nano-carriers
Beck-Broichsitter, M., Merkel, O. M., & Kissel, T. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.004 · Cited by 200 · see citing works
Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model
Roa, W., Azarmi, S., Alhallak, K., Finlay, W. H., Magliocco, A. M., & Löbenberg, R. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.035 · Cited by 181 · see citing works
Self-citation
Inhaled nanomaterials and the respiratory microbiome: clinical, immunological and toxicological perspectives
Poh, T. Y., Ali, N. A. B. M., Aogáin, M. M., Kathawala, M. H., Setyawati, M. I., Ng, K. W., & Chotirmall, S. H. (2018) · Particle and Fibre Toxicology · doi:10.1186/s12989-018-0282-0 · Cited by 172 · see citing works
Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines
Guo, Y., Bera, H., Shi, C., Zhang, L., Cun, D., & Yang, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.015 · Cited by 172 · see citing works
Nanoparticulate drug delivery systems for cancer chemotherapy
Saha, R. N., Sekar, V., Bende, G., & Snehalatha, M. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.510804 · Cited by 163 · see citing works
“It is expected that within 10 years, 50% of all drug delivery and design approaches may be shifted to Nanoparticulate Drug Delivery Systems (NPDDS) technology (Gill et al. 2007).”
BackgroundInfluential
A database for deliquescence and efflorescence relative humidities of compounds with atmospheric relevance
Peng, C., Chen, L., & Tang, M. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.11.021 · Cited by 164 · see citing works
Nano-QSAR modeling for predicting biological activity of diverse nanomaterials
Singh, K. P., & Gupta, S. (2014) · RSC Advances · doi:10.1039/c4ra01274g · Cited by 152 · see citing works
Translational nanomedicine: status assessment and opportunities
Murday, J. S., Siegel, R. W., Stein, J. A., & Wright, J. F. (2009) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2009.06.001 · Cited by 146 · see citing works
Spray freeze drying for dry powder inhalation of nanoparticles
Ali, M. E., & Lamprecht, A. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.03.009 · Cited by 143 · see citing works
Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections
Günday-Türeli, N., Torge, A., Juntke, J., Schwarz, B., Schneider‐Daum, N., Türeli, A. E., Lehr, C., & Schneider, M. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.04.032 · Cited by 133 · see citing works
The formulation of nanomedicines for treating tuberculosis
Costa, A., Pinheiro, M., Magalhães, J., Ribeiro, R., Seabra, V., Reis, S., & Sarmento, B. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.012 · Cited by 123 · see citing works
Micro- and nanocarrier-mediated lung targeting
Kurmi, B. D., Kayat, J., Gajbhiye, V., Tekade, R. K., & Jain, N. K. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.492212 · Cited by 122 · see citing works
“Drug delivery to lungs is an attractive horizon owing to the large surface area of the alveolar region, lower thickness of the epithelial barrier, extensive vascularization, relatively low proteolytic activity in the alveolar space as compared with other routes of administration and absence of the first-pass metabolis…”
Background
Biphasic release of gentamicin from chitosan/fucoidan nanoparticles for pulmonary delivery
Huang, Y., Li, R., Chen, J.-Y., & Chen, J. (2015) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2015.11.072 · Cited by 123 · see citing works
“The proposed mechnism of NP deposition is Brownian diffusion, which occurs in the cinar region of the lungs (Gill et al., 2007).”
Background
Respirable nanocarriers as a promising strategy for antitubercular drug delivery
Mehanna, M. M., Mohyeldin, S. M., & Elgindy, N. A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.038 · Cited by 119 · see citing works
Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro
Beck‐Broichsitter, M., Ruppert, C., Schmehl, T., Guenther, A., Betz, T., Bakowsky, U., Seeger, W., Kissel, T., & Gessler, T. (2010) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2010.10.007 · Cited by 116 · see citing works
Liposomes as Drug Delivery Systems for The Treatment of TB
Pinheiro, M., Lúcio, M., Lima, J. L. F. C., & Reis, S. (2011) · Nanomedicine · doi:10.2217/nnm.11.122 · Cited by 115 · see citing works
Recent applications and strategies in nanotechnology for lung diseases
Zhong, W., Zhang, X., Zeng, Y., Lin, D., & Wu, J. (2021) · Nano Research · doi:10.1007/s12274-020-3180-3 · Cited by 115 · see citing works
Biodistribution of Amikacin Solid Lipid Nanoparticles after Pulmonary Delivery
Varshosaz, J., Ghaffari, S., Mirshojaei, S. F., Jafarian‐Dehkordi, A., Atyabi, F., Kobarfard, F., & Azarmi, S. (2013) · BioMed Research International · doi:10.1155/2013/136859 · Cited by 110 · see citing works
“As Zetasizer and SEM pictures confirmed the optimized SLNs had suitable size (<200 nm) and zeta potential (+7mV) to escape from being uptaken by the alveolar macrophages [5, 6, 12].”
BackgroundSelf-citation
Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer
Meenach, S. A., Anderson, K. W., Hilt, J. Z., McGarry, R. C., & Mansour, H. M. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.05.012 · Cited by 110 · see citing works
Inhaled nanoparticles–An updated review
Praphawatvet, T., Peters, J. I., & Williams, R. O. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119671 · Cited by 101 · see citing works
Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: In vitro and in vivo studies
Jyoti, K., Kaur, K., Pandey, R. S., Jain, U. K., Chandra, R., & Madan, J. (2015) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2014.12.092 · Cited by 82 · see citing works
Advances in Device and Formulation Technologies for Pulmonary Drug Delivery
Chan, J. G. Y., Wong, J., Zhou, Q. T., Leung, S. S. Y., & Chan, H. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0114-y · Cited by 82 · see citing works
“ability, chemical composition, particle size, and local concentration (123, 124).”
Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols
Mansour, H. M., Meenach, S. A., Vogt, McGarry, Anderson, �., & Hilt, J. Z. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s30724 · Cited by 77 · see citing works
“Synthetic DPPC (molecular weight 734.039 g/mol, .”
Influential
Synthesis and in vitro study of cisplatin-loaded Fe 3 O 4 nanoparticles modified with PLGA-PEG 6000 copolymers in treatment of lung cancer
Nejati‐Koshki, K., Abbasi, M. M., Ebrahimi, E., et al. (2014) · Journal of Microencapsulation · doi:10.3109/02652048.2014.940011 · Cited by 76 · see citing works
“, 2007) including second-hand smoke (Gill et al., 2007; Roy et al., 2011).”
Background
Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles
Beck‐Broichsitter, M., Ruppert, C., Schmehl, T., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.10.016 · Cited by 66 · see citing works
Onco-Receptors Targeting in Lung Cancer via Application of Surface-Modified and Hybrid Nanoparticles: A Cross-Disciplinary Review
Sabir, F., Qindeel, M., Zeeshan, M., Ain, Q. U., Rahdar, A., Barani, M., González, E., & Aboudzadeh, M. A. (2021) · Processes · doi:10.3390/pr9040621 · Cited by 55 · see citing works
“Nanoparticles produce pulmonary toxicity by oxidative stress because of the production of reactive oxygen species within the biological system [137].”
Background
Pulmonary drug delivery applications of natural polysaccharide polymer derived nano/micro-carrier systems: A review
Balde, A., Kim, S., Benjakul, S., & Nazeer, R. A. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.09.116 · Cited by 52 · see citing works
Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: Design of experiments approach
Günday-Türeli, N., Türeli, A. E., & Schneider, M. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.10.025 · Cited by 47 · see citing works
Mechanisms of toxicity induced by SiO2 nanoparticles of in vitro human alveolar barrier: effects on cytokine production, oxidative stress induction, surfactant proteins A mRNA expression and nanoparticles uptake
Farcal, L. R., Uboldi, C., Méhn, D., Giudetti, G., Nativo, P., Ponti, J., Gilliland, D. D., Rossi, F., & Bal‐Price, A. (2012) · Nanotoxicology · doi:10.3109/17435390.2012.710658 · Cited by 46 · see citing works
“strated that the unique physiochemical properties of nanoparticles are attributed to their small size, large surface area, chemical composition, surface reactivity, charge, shape and interactions with different kinds of proteins (Oberdorster et al. 2005; Gill et al. 2007).”
Background
Secondary cytotoxicity mediated by alveolar macrophages: A contribution to the total efficacy of nanoparticles in lung cancer therapy?
Alhallak, K., Azarmi, S., Anwar‐Mohamed, A., Roa, W., & Löbenberg, R. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.05.002 · Cited by 45 · see citing works
“The lungs, as a part of the MPS, are extensively rich in alveolar macrophages [10].”
BackgroundSelf-citation
Controllable preparation and formation mechanism of BSA microparticles using supercritical assisted atomization with an enhanced mixer
Wang, Q., Guan, Y., Yao, S., et al. (2010) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2010.12.002 · Cited by 44 · see citing works
Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments
Gupta, C., Jaipuria, A., & Gupta, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010139 · Cited by 43 · see citing works
“One major risk involved is pulmonary toxicity due to the high concentration of drugs in the lungs [14].”
Background
Skin targeting by chitosan/hyaluronate hybrid nanoparticles for the management of irritant contact dermatitis: In vivo therapeutic efficiency in mouse-ear dermatitis model
Abuelella, K. E., Abd-Allah, H., Soliman, S. M., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123458 · Cited by 43 · see citing works
Formulating protein therapeutics into particulate forms
Yang, S., Yuan, W., & Jin, T. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903156374 · Cited by 43 · see citing works
“To ensure that therapeutics reach pulmonary alveoli (which represent sufficient area of mucosa), protein-loading particles have to be formulated in the range of 1 – 5 μm in diameter so that they can be carried in by the airflow of respiration to the destination without earlier deposition and exhalation [3,4].”
Background
Feasibility Study of Mesoporous Silica Particles for Pulmonary Drug Delivery: Therapeutic Treatment with Dexamethasone in a Mouse Model of Airway Inflammation
Gulin-Sarfraz, T., Jonasson, S., Wigenstam, E., et al. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11040149 · Cited by 41 · see citing works
“Drug-loaded particles, compared to free drugs, also have a higher ability to reach the lower parts of the lungs [26,27].”
Background
Pulmonary delivery of anti-inflammatory agents
Ali, M. E., McConville, J. T., & Lamprecht, A. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.993968 · Cited by 37 · see citing works
“Pulmonary drug delivery has many advantages over other routes of drug administration and drug absorption, including the large alveolar surface area, extensive vascularization (about 5 l/min), low thickness of the epithelial barrier and the limited enzymatic activity compared to other routes of administration [7-9].”
Background
Pulmonary Toxicity of Polysorbate-80-coated Inhalable Nanoparticles; In vitro and In vivo Evaluation
Alhallak, K., Azarmi, S., Sun, C., Lai, P. K., Prenner, E. J., Roa, W., & Löbenberg, R. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9190-4 · Cited by 37 · see citing works
Self-citation
Evaluating the Controlled Release Properties of Inhaled Nanoparticles Using Isolated, Perfused, and Ventilated Lung Models
Beck‐Broichsitter, M., Schmehl, T., Seeger, W., & Gessler, T. (2010) · Journal of Nanomaterials · doi:10.1155/2011/163791 · Cited by 36 · see citing works
“However, the relevance of these findings for the in vivo translocation of inhaled ultrafine particles remains to be established, owing to the fact that polymeric nanoparticles are currently under investigation as potential drug delivery systems to the lung [95].”
Background
Release, Characterization, and Safety of Nanoencapsulated Food Ingredients
Jafari, S. M., Esfanjani, A. F., Katouzian, I., & Assadpour, E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809740-3.00010-6 · Cited by 49 · see citing works
Targeted delivery of anti-tuberculosis drugs to macrophages: targeting mannose receptors
Filatova, L. Y., Klyachko, N. L., & Kudryashova, E. V. (2018) · Russian Chemical Reviews · doi:10.1070/rcr4740 · Cited by 35 · see citing works
Current advances in drug delivery of nanoparticles for respiratory disease treatment
de Menezes, B. R. C., Rodrigues, K. F., Schatkoski, V. M., Pereira, R. M., Ribas, R. G., Montanheiro, T. L. D. A., & Thim, G. P. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01783c · Cited by 34 · see citing works
Targeted pulmonary drug delivery in coronavirus disease (COVID-19) therapy: A patient-specific in silico study based on magnetic nanoparticles-coated microcarriers adhesion
Ebrahimi, S., Shamloo, A., Alishiri, M., Mofrad, Y. M., & Akherati, F. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121133 · Cited by 34 · see citing works
Nanogold-Gallate Chitosan-Targeted Pulmonary Delivery for Treatment of Lung Cancer
Komenek, S., Luesakul, U., Ekgasit, S., et al. (2016) · AAPS PharmSciTech · doi:10.1208/s12249-016-0644-6 · Cited by 34 · see citing works
Deposition of Inhaled Ultrafine Aerosols in Replicas of Nasal Airways of Infants
Golshahi, L., Finlay, W. H., Olfert, J. S. S., et al. (2010) · Aerosol Science and Technology · doi:10.1080/02786826.2010.488256 · Cited by 31 · see citing works
“Nanomedicine, including the use of nanoparticles, has potential for the therapeutic treatment of diseases via manipulation of particle characteristics such as size, surface chemistry, surface charge, and surface area (Gill et al. 2007).”
Polymeric Nanoparticles for Inhaled Vaccines
Al‐Nemrawi, N. K., Darweesh, R. S., Alshriem, L. A., Al-Qawasmi, F. S., Emran, S. O., Khafajah, A. S., & Abu‐Dalo, M. (2022) · Polymers · doi:10.3390/polym14204450 · Cited by 30 · see citing works
Anti-SARS-CoV-1 and −2 nanobody engineering towards avidity-inspired therapeutics
Obeng, E. M., Dzuvor, C. K. O., & Danquah, M. K. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101350 · Cited by 26 · see citing works
Liposomes-and niosomes-based drug delivery systems for tuberculosis treatment
Bekraki, A. I. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819811-7.00007-2 · Cited by 28 · see citing works
Aptamers as promising nanotheranostic tools in the COVID ‐19 pandemic era
Dzuvor, C. K. O., Tettey, E. L., & Danquah, M. K. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1785 · Cited by 25 · see citing works
“In addition, these platforms possess superb bioavailability, longer blood circulatory properties, and pharmacokinetics profile (Gill et al., 2007; Li et al., 2018), which makes them perfect for curbing lung-related or respiratory diseases of which COVID-19 is no exception.”
Background
Nontoxic impact of PEG-coated gold nanospheres on functional pulmonary surfactant-secreting alveolar type II cells
Bouzas, V., Haller, T., Hobi, N., Felder, E., Pastoriza‐Santos, I., & Pérez‐Gil, J. (2013) · Nanotoxicology · doi:10.3109/17435390.2013.829878 · Cited by 25 · see citing works
“The size of NPs is the critical parameter that defines the site of deposition within the respiratory tract (Gill et al. 2007).”
Background
Targeted drug therapy in nonsmall cell lung cancer: clinical significance and possible solutions-part II (role of nanocarriers)
Yadav, K. S., Upadhya, A., & Misra, A. R. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1832989 · Cited by 24 · see citing works
State of the Art of Nanobiotechnology Applications in Neglected Diseases
Durán, N., Marcato, P. D., Teixeira, Z., Durán, M., Costa, F. T. M., & Brocchi, M. (2009) · Current Nanoscience · doi:10.2174/157341309789378069 · Cited by 23 · see citing works
“Nanotechnology in the field of pharmaceutical biotechnology has had a positive influence on medical and pharmaceutical sciences [1-7].”
Background
Biogenic Nano-Synthesis; towards the Efficient Production of the Biocompatible Gold Nanoparticles
Gajanan, G., Eom, C., Kim, S. W., et al. (2010) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2010.31.10.2771 · Cited by 23 · see citing works
DRUG-RESISTANT TUBERCULOSIS: RECENT APPROACH IN POLYMER BASED NANOMEDICINE
Shaji, J., & Shaikh, M. (2016) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2016v8i10.11295 · Cited by 21 · see citing works
“Moreover, the NPs can be engineered by attaching different ligands for active targeting of an area of interest like alveolar macrophages (AMs) [43].”
Background
Improved camptothecin encapsulation and efficacy by environmentally sensitive block copolymer/chitosan/fucoidan nanoparticles for targeting lung cancer cells
Don, T., Hong, Y., Jheng, P., Chuang, E., & Huang, Y.-C. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133901 · Cited by 21 · see citing works
Relevance of Two-Dimensional Brownian Motion Dynamics in Applying Nanoparticle Tracking Analysis
der Meeren, P. V., Kasinos, M., & Saveyn, H. G. M. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-953-2_42 · Cited by 21 · see citing works
Biocompatible Nanovesicular Drug Delivery Systems with Targeting Potential for Autoimmune Diseases
Neupane, Y. R., Mahtab, A., Siddiqui, L., Singh, A., Gautam, N., Rabbani, S. A., Goel, H., & Talegaonkar, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200523174108 · Cited by 21 · see citing works
High-voltage, electric field-driven micro/nanofabrication for polymeric drug delivery systems
Xie, Y., & Castracane, J. (2009) · IEEE Engineering in Medicine and Biology Magazine · doi:10.1109/memb.2008.931013 · Cited by 20 · see citing works
Core–shell drug carriers: liposomes, polymersomes, and niosomes
Dan, N. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46143-6.00002-6 · Cited by 21 · see citing works
Development, characterisation and pharmacoscintigraphic evaluation of nano-fluticasone propionate dry powder inhalation as potential antidote against inhaled toxic gases
Ali, R., Mittal, G., Ali, R., et al. (2013) · Journal of Microencapsulation · doi:10.3109/02652048.2013.764937 · Cited by 18 · see citing works
“…Carvalho et al., 2011), local action, low enzyme activity, immediate therapeutic concentration at low dose, high safety index and increased patient compliance due to non-invasive nature (Gill et al., 2007; Mansour et al., 2009) makes it a preferred route for treating various respiratory disorders.”
Background
Ecotoxicity studies of two atrazine nanoformulations: From the evaluation of stability in media to the effects on aquatic organisms
Castanha, R. F., Pereira, A. D. E. S., Villarreal, G. P. U., et al. (2023) · Environmental Pollution · doi:10.1016/j.envpol.2023.122235 · Cited by 17 · see citing works
Harnessing sortase A transpeptidation for advanced targeted therapeutics and vaccine engineering
Obeng, E. M., Fulcher, A. J., & Wagstaff, K. M. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108108 · Cited by 20 · see citing works
Experimental sensing and density functional theory study of an ionic liquid mediated carbon nanotube modified carbon-paste electrode for electrochemical detection of metronidazole
Saghravanian, M., Ebrahimi, M., Es’haghi, Z., et al. (2017) · South African Journal of Chemistry · doi:10.17159/0379-4350/2017/v70a5 · Cited by 17 · see citing works
Modern Strategies of Drug Therapy: Multi-Target Drug Delivery, Bioimaging, Diagnostics
Fedorova, O. V., Ovchinnikova, I. G., Rusinov, G. L., Avdeeva, V. V., Zhdanov, А. P., Zhizhin, K. Y., Kuznetsov, N. T., Zakharova, L. Y., Kuznetsova, D. A., Razuvayeva, Y. S., et al. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606726 · Cited by 15 · see citing works
In Vitro Investigation of Influences of Chitosan Nanoparticles on Fluorescein Permeation into Alveolar Macrophages
CHACHULI, S. H. M., Nawaz, A., Shah, K. U., et al. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1893-5 · Cited by 14 · see citing works
Reducing the cytotoxicity of magnesium oxide nanoparticles using cerium oxide shell coating: An in vitro and in vivo study
Soltani, M., Karami‐Mohajeri, S., Ranjbar, M., Ahmadi, N., Jafari, E., Mandegari, A., & Heydari, M. R. (2023) · Ceramics International · doi:10.1016/j.ceramint.2023.01.069 · Cited by 13 · see citing works
Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas Aeruginosa Infection in Cystic Fibrosis – A Review
Günday-Türeli, N., Türeli, A. E., & Schneider, M. (2014) · Drug Delivery Letters · doi:10.2174/2210303104666140222002101 · Cited by 12 · see citing works
Vesicle-based drug carriers
Dan, N. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813627-0.00001-6 · Cited by 14 · see citing works
Radiation Protection with Nanoparticles
Baker, C. H. (2011) · Science Publishers eBooks · doi:10.1201/b11076-15 · Cited by 12 · see citing works
Highly efficient pulmonary delivery of levo-tetrahydropalmatine using γ-cyclodextrin metal-organic framework as a drug delivery platform
Nie, Q., Wang, C., Xu, H., Mittal, P., Naeem, A., Zhou, P., Li, H., Zhang, Y., Guo, T., Sun, L., et al. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104296 · Cited by 13 · see citing works
RECENT MODALITIES IN DRUG DELIVERY VIA INHALATION THERAPY – AN ADVANCED TREATMENT STRATEGY FOR PULMONARY CARCINOMA
Rajendran, R., Rajan, B., Ganesan, N., & Devaki, T. (2015) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 10 · see citing works
Nanocarrier-Assisted Antimicrobial Therapy Against Intracellular Pathogens
Kumar, L., Verma, S., Vaidya, B., & Mehra, N. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46152-8.00013-5 · Cited by 11 · see citing works
Targeted Delivery of Surface-Modified Nanoparticles: Modulation of Inflammation for Acute Lung Injury
Nguyen, H. X. (2019) · Springer eBooks · doi:10.1007/978-3-030-06115-9_17 · Cited by 11 · see citing works
Characterization and performance evaluation of pH-sensitive drug delivery of mesoporous silica with honeycomb structure for treatment of cancer
Duan, L., Shirazian, S., & Zare, M. H. (2024) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2024.124680 · Cited by 12 · see citing works
Hygroscopicity and the water-polymer interaction parameter of nano-sized biodegradable hydrophilic substances
Mao, C.-N., Malek, K. A., & Asa-Awuku, A. (2021) · Aerosol Science and Technology · doi:10.1080/02786826.2021.1931012 · Cited by 9 · see citing works
“Additionally, organic nano-particles are intentionally produced and inhaled for aerosol therapy (Muralidharan et al. 2015; Azarmi, Roa, and L€obenberg 2008; Gill et al. 2007; Agnihotri, Mallikarjuna, and Aminabhavi 2004; Malcolmson and Embleton 1998).”
Background
Polycaprolactone Nanoparticles Boost Licofelone Transdermal Delivery for Osteoarthritis: In Vitro Characterization, Ex Vivo Permeability, and In Vivo Efficacy
Abuelella, K. E., Mosallam, S., El-Gazar, A. A., et al. (2025) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-025-10240-z · Cited by 7 · see citing works
Biophysical analysis of gelatin and PLGA nanoparticle interactions with complex biomimetic lung surfactant models
Daear, W., Sule, K., Lai, P. K., & Prenner, E. J. (2022) · RSC Advances · doi:10.1039/d2ra02859j · Cited by 7 · see citing works
Self-citation
Dielectric Properties Tangential to the Interface in Model Insoluble Monolayers: Theoretical Assessment
Shushkov, P., Tzvetanov, S., Ivanova, A., et al. (2008) · Langmuir · doi:10.1021/la703616c · Cited by 7 · see citing works
Nanocrystals based mucosal delivery system: research advances
Liu, Y., Shuai, S., Huang, G. S., Chen, Y., Shen, B., & Yue, P. (2021) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2022.2053985 · Cited by 6 · see citing works
TLR7 agonist loaded airway epithelial targeting nanoparticles stimulate innate immunity and suppress viral replication in human bronchial epithelial cells
Kan, S., Grainge, C., Nichol, K., Reid, A. T., Knight, D. A., Sun, Y. J., Bartlett, N. W., & Liang, M. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121586 · Cited by 6 · see citing works
Nanoparticle Functionalization for Brain Targeting Drug Delivery and Diagnostic
Gomes, M. J., Mendes, B. B., Martins, S., & Sarmento, B. F. C. C. (2015) · Springer eBooks · doi:10.1007/978-3-319-15338-4_42 · Cited by 6 · see citing works
Engineering porous vaterite CaCO₃ nanostructures via alcohol–surfactant coordination in co-precipitation: A facile route to tunable drug-carrier platforms
Kim, S.-Y., Kim, S.-Y., Kang, M.-K., et al. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115592 · Cited by 4 · see citing works
Inhalable Polymeric Micro and Nano-immunoadjuvants for Developing Therapeutic Vaccines in the Treatment of Non-small Cell Lung Cancer
Dondulkar, A., Akojwar, N., Katta, C. B., Khatri, D. K., Mehra, N. K., Singh, S. B., & Madan, J. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666211104155604 · Cited by 4 · see citing works
Pulmonary Drug Delivery with Nanoparticles
Beck‐Broichsitter, M., Schmehl, T., Seeger, W., & Gessler, T. (2011) · Science Publishers eBooks · doi:10.1201/b11076-13 · Cited by 4 · see citing works
Nanomedicines in Tuberculosis: Diagnosis, Therapy and Nanodrug Delivery
Dakkah, A. N., Bataineh, Y. A., Al-Jaidi, B. A., Bayan, M. F., & Nimer, N. A. (2020) · Engineering materials · doi:10.1007/978-3-030-36260-7_13 · Cited by 3 · see citing works
Development and Characterization of Nanocarrier Systems for the Delivery of Antitubercular Drugs
Ribeiro, R. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/b6v3-t472 · Cited by 3 · see citing works
Carbon Dots with Tunable Charge as Mucus-Penetrating Gene Carriers
Arca, S., Witjaksono, C., Pons, F., & Lebeau, L. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107222 · Cited by 4 · see citing works
Improvement in the bioavailability of poorly water-soluble drugs via pulmonary delivery of nanoparticles
Yang, W. P. (2009) · Texas ScholarWorks (Texas Digital Library) · Cited by 2 · see citing works
Applications of pulsed laser ablation for enhanced gold nanofluids
Hur, T.-B., Phuoc, T. X., Chyu, M. K., et al. (2012) · Journal of Applied Physics · doi:10.1063/1.4752876 · Cited by 2 · see citing works
Nanoparticles
Rasulev, B., Leszczyńska, D., & Leszczyński, J. (2011) · IGI Global eBooks · doi:10.4018/978-1-60960-860-6.ch003 · Cited by 2 · see citing works
“…experiments are published in the last few years (Choi et al, 2008; Lewinski et al, 2008; Franklin et al, 2007; Duffin et al, 2007; Fiorito, 2007; Gill et al, 2007;Powers et al, 2007; Medina et al, 2007; Moore, 2006; Karakoti et al, 2006; Moss & Wong, 2006; Lee & Cho, 2006; Tsuji et al, 2006;…”
Background
Toxicological Aspects of Polymer Nanoparticles
Irache, J. M., Martín‐Arbella, N., Ojer, P., Azqueta, A., & de Ceráin, A. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-41421-8_16 · Cited by 4 · see citing works
Nanopharmaceuticals
Yurdasiper, A., Arıcı, M., & Özyazıcı, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-40016-9.00007-5 · Cited by 2 · see citing works
Asymmetric particles for pulmonary drug delivery
Köhler, D. (2010) · Max Planck Institute for Plasma Physics · doi:10.22028/d291-22691 · Cited by 2 · see citing works
“1μm in the alveoli) make the lung an interesting drug delivery route due to the high drug absorption and the ability to circumvent the first pass effect [7, 8].”
Background

Amiodarone pulmonary toxicity — three unusual manifestations
McNeil, K., Firouz‐Abadi, A., Oliver, W., et al. (1992) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1992.tb01702.x · Cited by 12 · see citing works
Investigation on baseline toxicity to rats based on aliphatic compounds and comparison with toxicity to fish: Effect of exposure routes on toxicity
He, J., Fu, L., Wang, Y., et al. (2014) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2014.06.019 · Cited by 12 · see citing works
Amiodarone Pulmonary Toxicity
Martin, W. J., Osborn, M. J., & Douglas, W. W. (1986) · CHEST Journal · doi:10.1378/chest.89.5.768-b · Cited by 29 · see citing works
[Pulmonary toxicity of antineoplastic agents--with special reference to current findings on pulmonary toxicity of bleomycin].
Okuma, K., & Ota, K. (1982) · PubMed
ON THE DETERMINATION OF THE TOXICITY OF NEOARSPHENAMINE I. THE INCREASE IN TOXICITY ON EXPOSURE TO AIR
Morrell, C., & Chapman, C. W. (1933) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)05997-x · Cited by 1 · see citing works

Authors: Gill, S., Löbenberg, R., Ku, T., Azarmi, S., Roa, W., & Prenner, E. J.
ORCID: Löbenberg, Raimar
Roa, Wilson
Prenner, Elmar J.
Venue: Journal of Biomedical Nanotechnology
Publisher: American Scientific Publishers
Published: 2007-06-01
Volume: 3
Issue: 2
Pages: 107-119
ISSN: 1550-7033 (ISSN-L)
0000-0000
DOI: 10.1166/jbn.2007.015
OpenAlex: W2329541536
Cited by: 118
References: 0
Citations by year: 2026: 4 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 7 · 2021: 9 · 2020: 6 · 2019: 5 · 2018: 4 · 2017: 6 · 2016: 8 · 2015: 5 · 2014: 8 · 2013: 7 · 2012: 7
FWCI: 6.60
Type: journal article
Language: en
Open access: closed
Locations: Journal of Biomedical Nanotechnology (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords: nanoparticles, pulmonary drug delivery, mechanism of action, nanoparticle toxicity, aerosolized nanoparticles, lung deposition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nanoparticles: Characteristics, Mechanisms of Action, and Toxicity in Pulmonary Drug Delivery—A Review

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cited by

Related

Record

About these checks